<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The cumulative results and long-term follow-up of <z:hpo ids='HP_0000001'>all</z:hpo> patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treated at the Uganda <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> Institute Kampala are reported </plain></SENT>
<SENT sid="1" pm="."><plain>The annual admission rate is 29 </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> patients commonly present with jaw swelling (72%), <z:hpo ids='HP_0003270'>abdominal swelling</z:hpo> (56%) and central <z:mp ids='MP_0008912'>nervous</z:mp> system involvement (30%) </plain></SENT>
<SENT sid="3" pm="."><plain>Complete response rate is achieved in a high proportion of patients (81%) </plain></SENT>
<SENT sid="4" pm="."><plain>About 50% of these relapse, equal numbers relapsing before and after 3 months </plain></SENT>
<SENT sid="5" pm="."><plain>The most important factor influencing remission duration and survival is disease stage </plain></SENT>
<SENT sid="6" pm="."><plain>Other important factors are treatment protocols and, to a lesser extent, the type of relapse </plain></SENT>
<SENT sid="7" pm="."><plain>Central <z:mp ids='MP_0008912'>nervous</z:mp> system relapse does not necessarily augur poor prognosis as second remissions and long-term survival can be achieved with appropriate therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Presently 25% of <z:hpo ids='HP_0000001'>all</z:hpo> treated patients have survived free of disease well beyond 5 years </plain></SENT>
</text></document>